Cardiotoxicity of antracycline treatment in the light of new biochemical diagnostic options

Czech version

Authors: D. Urbanová; B. Mladosievičová
Authors‘ workplace: Ústav patologickej fyziológie, Oddelenie klinickej patofyziológie Lekárskej fakulty UK Bratislava, Slovenská republika, prednosta doc. MUDr. Marián Bernadič, CSc., mim. prof.
Published in: Vnitř Lék 2007; 53(6): 669-677
Category: Reviews

Overview

Oncologic patients often receive treatment which is potentially cardiotoxic. Cardiotoxic complications range from fairly mild (relatively benign arrhythmias) to life threatening conditions (ischemia/myocardial infarction, heart failure, cardiomyopathy). The toxic effect of chemotherapy drugs may impair the integrity of the sarcomere, cause the release of bioactive substances into both tissues and the circulatory system and, consequently, cause necrosis/apoptosis of myocytes. A marker of the scope and severity of damage to the myocardium can be assessed by measuring the levels of cardiac markers in the serum. Cardiologic research is currently focused on the identification of new biochemical markers with a high degree of specificity, sensitivity and predictive value that might be used in the timely detection of myocardial abnormalities. The informative value of currently measured cardiac markers (myoglobin, CK-MB mass, CK-MB, and partly CK) is insufficient. There is growing evidence of the usefulness of natriuretic peptides and cardiac troponins in the diagnosing and monitoring of early and late, clinical and subclinical cardiotoxiticy resulting from anti-tumour therapy. The article summarises clinical studies concerning the diagnosis and monitoring of cardiotoxicity with the use of natriuretic peptides and cardiac troponins in former oncological patients.

Key words:
cardiotoxicity – anthracyclines – cardiac troponins – natriuretic peptides

Sources

1. Mladosievičová B. Patofyziológia a klinika kardiotoxicity cytostatík. Acta chemotherapeutica 2003; 5: 67-76.

2. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.

3. Mertens A, Yasui Y, Neglia JP et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivors Study. J Clin Oncol 2001; 19: 3163-3172.

4. Singal PK, Iliskovic. N Doxorubicin-induced cardiomyopthy. N Engl J Med 1998; 339: 900-905.

5. Giantris A, Abdurrahman L, Hinkle A et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998; 27: 53-68.

6. Simbre VC, Duffy SA, Dadlani GH et al. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 2005; 7: 187-202.

7. Weiss RB. The anthracyclines: will we ever find a better doxorubicine? Semin Oncol 1992; 19: 670-686.

8. Wilson KS. Anthracyclines in early breast cancer. N Engl J Med 2006; 355: 845.

9. Elbl L, Vášová I, Krejčí M et al. Vliv vysokodávkované chemoterapie s následnou transplantací krvetvorných buněk na funkci levé komory srdeční u nemocných s maligními lymfomy léčenými doxorubicinem v primární chemoterapii. Vnitř Lék 2006; 52: 221-231.

10. Elbl L, Vášová I, Navrátil M et al. Pozdní kardiotoxicita u nemocných léčených pro maligní lymfomy chemoterapií s doxorubicinem. Vnitř Lék 2006; 52: 328-338.

11. Herman EH, Ferrans VJ Pathophysiology of anthracyclines cardiotoxicity, 25-34. In: Bricker JT, Green DM, D’Angio GJ Cardiac toxicity after treatment for childhood cancer. Wiley-Liss, New York 1993.

12. Parker MA, King V, Howard KP et al. Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers. Biochim Biophys Acta 2001; 1514: 206-216.

13. Kim Y, Ma AG, Kitta K et al. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 2003; 63: 368-377.

14. Arai M, Yoguchi A, Takizawa T. Mechanisms of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca-ATPase gene transcription. Mol Med 2000; 86: 8-14.

15. Tolba K, Deliargyris EN. Cardiotoxicity of cancer therapy. Cancer Invest 1999; 17: 408-422.

16. Caulfield JB, Bittner V. Cardiac matrix alterations induced by adriamycin. Am J Pathol 1988; 133: 298-230.

17. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 33: S2-S7.

18. Wolf MB, Baynes JW. The anticancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 2006; 1760: 267-271.

19. Dolci A, Dominici R, Cardinale D et al. Biochemical markers for predicting chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. G Ital Cardiol 2006; 7: 604-611.

20. Urbanova D, Urban L, Carter A et al. Cardiac troponins - biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma 2006; 53: 183-190.

21. Adamcova M, Sterba M, Simunek T et al. Troponin as a marker of myocardial damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005; 4: 457-472.

22. Katus HA, Remppis A, Looser S et al. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol 1989; 21: 1349-1353.

23. Ebashi S, Wakabayashi T, Ebashi F. Troponin and its components. J Biochem 1971; 69: 441-445.

24. Špirková Z, Daňová K, Pecháň I et al. Interferencie v analýzach kardiálnych troponínov, 32. In: Kardiomarkery. Bratislava: Phonec Agency 2005.

25. Wallace TW, Abdullah SM, Drazner MH et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113: 1958-1965.

26. Wallace KB, Hausner E, Herman E et al. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004; 32: 106-121.

27. Adamcova M, Geršl V, Hrdina R et al. Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol 1999; 125: 268-274.

28. Horwich TB, Patel J, MacLellan WR et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833-838.

29. Communal C, Sumandea M, de Tombe P et al. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 2002; 99: 6252-6256.

30. Adamcova M, Sterba M, Simunek T et al. Myocardial regulatory proteins and heart failure. Eur J Heart Fail 2006; 8: 333-342.

31. Seino Y, Tomita Y, Nagae Y et al. Cardioprotective effeects of ACE-inhibitor (Cilazapril) on adriamycin cardiotoxicity in spontaneously hypertensive rats. Circulation 1993; 88: 1633.

32. O’Brien PJ, Dameron GW, Beck ML et al. Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Science 1997; 47: 486-495.

33. Herman EH, Zhang J, Lipshultz SE et al. Correlation between serum levels of cardiac troponin T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17: 2237-2243.

34. Bertinchant JP, Polge A, Juan LM et al. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy in rats and their relationship with echocardiographic and histological findings. Clin Chim Acta 2003; 329: 39-51.

35. Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin induced cardiomyopathy in rats. Circ J 2004; 68: 163-167.

36. Lipshultz SE, Rifai N, Sallan SE et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641-2648.

37. Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-153.

38. Auner HW, Tinchon C, Linkesch W et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218-222.

39. Kilickap S, Barista I, Akgul E et al. CTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16: 798-804.

40. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. JACC 2000; 36: 517-522.

41. Koseoglu V, Berberoglu S, Karademir S et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin? Turk J Pediatr 2005; 47: 17-22.

42. Soker M, Kervancioglu M Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005; 26: 1197-1202.

43. Mathew P, Suarez W, Kip K et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001; 19: 352-359.

44. Špirková Z, Daňová K, Pecháň I et al. Kardiomarkery pri srdcovom zlyhaní - natriuretické peptidy, 101-107. In: Kardiomarkery. Bratislava: Phonec Agency 2005.

45. Sudoh T, Kangawa K, Minamino N et al. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.

46. Mair J Role of cardiac natriuretic peptide testing in heart failure (Editorial). Clin Chem 2002; 48: 977-978.

47. Ricciardi G, Pieragnoli P, Colella A et al. Role of natriuretic peptides in heart failure patients with special reference to those on cardiac resynchronization therapy. Minerva Cardioangiol 2006; 54: 743-752.

48. Remes J, Miettinien H, Reunanen A et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315-321.

49. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140.

50. Murín J, Kamenský G, Goncalvesová E et al. Komentár k Odporúčaniam Európskej kardiologickej spoločnosti pre diagnostiku a liečbu pacientov s chronickým srdcovým zlyhávaním. Cardiol 2006; 15: 55-59.

51. Bauch M, Ester A, Kimura B et al. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992; 69: 1492-1497.

52. Hayakawa H, Komada Y, Hirayama M et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37: 4-9.

53. Lipshultz SE, Hinkle AS, French CA et al. Accelerated atherosclerosis contributes to elevated global risk for premature symptomatic cardiovascular disease in survivors of childhood cancer. Abstract No: 3203, 2003; ASCO Annual Meeting

54. Germanakis I, Kalmanti M, Parthenakis F et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 2006; 108: 212-215.

55. Nousiainen T, Jantunen E, Vanninen E et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999; 62: 135-141.

56. Okumura H, Iuchi K, Yoshida T et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158-163.

57. Meinardi MT, van Veldhuisen DJ, Gietema JA et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746-2753.

58. Daugaard G, Lassen U, Bie P et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005; 7: 87-93.

59. Elbl L, Vášová I, Navrátil M et al. Srovnání plazmatických hladin B-natriuretického peptidu s echokardiografickými ukazateli funkce levé komory srdeční po léčbě doxorubicinem. Vnitř Lék 2006; 52: 563-570.

60. Horacek JM, Pudil R, Tichy M et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005; 52: 430-434.

61. Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136: 362-363.

62. Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006; 152: 828-834.

63. Clerico A, Zucchelli GC, Pilo A et al. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 2006; 44: 366-378.